References
- Steinman RM: The dendritic cell system and its role in im nogenicitv, Annu Rev Immunol 9;271-296, 1991 https://doi.org/10.1146/annurev.iy.09.040191.001415
- Paglia P, Chiodoni C, Rodolfo M, Colombo MP: Murine dritic cells loaded in vitro with soluble protein prime cyt xic T lymphocytes against tumor antigen in vivo. J Exp Med 183:317-322, 1996 https://doi.org/10.1084/jem.183.1.317
- Brossart P, Goldrath A W, Butz EA, Martin S, Bevan MJ: rus-mediated delivery of antigenic epitopes into dendti cells as a means to induce CTL. J Immunol 158;3270-3276, 1997
- Brossart P, Bevan MJ: Presentation of exogenous protein tigens on major histocompatibility complex class I molecu by dendritic cells: pathway of presentation and regulation cytokines. Blood 90;1594-1599, 1997
- Banchereau J. Steinman RM: Dendritic cells and the COnt of immunity. Nature 392;245-252, 1998 https://doi.org/10.1038/32588
- Cella M, Sallusto F, Lanzavecchia A: Origin, maturation antigen presenting function of dendritic cells. Curr Opin Immunol 9;10-16, 1997 https://doi.org/10.1016/S0952-7915(97)80153-7
- Porgador A, Gilhoa E: Bone marrow-generated dendritic c pulsed with a class I restricted peptide are potent indue of cytotoxic T lymphocytes. J Exp Med 182;255-260, 1995 https://doi.org/10.1084/jem.182.1.255
- Zitvogel L, Mayordomo JI, Tiandrawan T, DeLeo AB, Cl MR, Lotze MT: Therapy of murine tumors with turnor-p tide pulsed dendritic cells: dependence on T cells, B7 cos mulation. and T helper cell l-associated cytokines. J Exp Med 183;87-97, 1996 https://doi.org/10.1084/jem.183.1.87
- Bevan MJ: Cross-priming for a secondary cytotoxic respo to minor H antigen with H-2 congenic cells which do cross-react in the cytotoxic assay. J Exp Med 143;1283-128 1976 https://doi.org/10.1084/jem.143.5.1283
- Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pard D, Levitsky H: Role of bone marrow-derived cells in p senting MHC class I-restricted tumor antigens. Science 264; 961-965, 1994 https://doi.org/10.1126/science.7513904
- Reis e Sousa C, Germain RN: Major histocompatibility c plex class I presentation of peptides derived from soluble e ogenous antigen by a subset of cells engaged in phagocyte J Exp Med 182;841-851, 1995 https://doi.org/10.1084/jem.182.3.841
- Norbury CC, Chambers BJ. Prescott AR, Liunggren H Watts C: Constitutive macropinocytosis allows TAP-dep dent presentation of exogenous antigen on class I MHC molecules by bone marrow derived dendritic cells. Eur J Immunol 27:280-288. 1997 https://doi.org/10.1002/eji.1830270141
- Carbone FR. Kurts C. Bennett SR. Miller TF. Heath W Cross-presentation: a general mechanism for CTL immun and tolerance. Immunol Today 19;368-373. 1998 https://doi.org/10.1016/S0167-5699(98)01301-2
- Inaba K. Inaba M. Romani N. Aya H. Dequchi M. Ikeh S. Steinman RM: Generation of large numbers of dendr cells from mouse bone marrow cultures supplemented w granulocyte/macrophage colony-stimulating factor. J Exp Med 176:1693-1702. 1992 https://doi.org/10.1084/jem.176.6.1693
-
Sallusto F. Lanzavecchia A: Efficient presentation of solu antigen by cultured human dendritic cells is maintained zranulocvte/rnacrouhaee colony-stimulating factor plus in leukin-4 and downrezulated by tumor necrosis factor-
$\alpha$ . J Exp Med 179;1109-1118. 1994 https://doi.org/10.1084/jem.179.4.1109 - Romani N. Gruner S. Branz D. Karnozen E. Lenz A. Tr kenbacher B: Proliferating dendritic cell progenitors in man blood. J Exp Med 180;83-93. 1994 https://doi.org/10.1084/jem.180.1.83
- Hsu FT. Benike C. Faznoni F. Liles TM. Czerwinski D. T B: Vaccination of patients with B-cell lymphoma using au lozous antigen-pulsed dendritic cells. Nat Med 2:52-58. 1996 https://doi.org/10.1038/nm0196-52
- Nestle Fa. Aliiazic S. Gilliet M. Sun Y. Grabbe S. Dum R: Vaccination of melanoma patients with peptide- or tum lysate-pulsed dendritic cells. Nat Med 4;328-332. 1998 https://doi.org/10.1038/nm0398-328
- Murphy G. Tioa B. Ragde H. Kenny G. Boynton A: Ph I clinical trial: T-cell therapy for prostate cancer using auto gous dendritic cells pulsed with HLA-A0201 specific peptid from prostate-specific membrane antigen. Prostate 29;371-380. 1996 https://doi.org/10.1002/(SICI)1097-0045(199612)29:6<371::AID-PROS5>3.0.CO;2-B
- Murphy GP. Tjoa BA. Simmons ST. Tarisch T. Bowes V Ragde H: Infusion of dendritic cells pulsed with HLA-A specific prostate-specific membrane antigen oeotides: a pha II prostate vaccine trial involving patients with hormone fractory metastatic disease. Prostate 38:73-78. 1999 https://doi.org/10.1002/(SICI)1097-0045(19990101)38:1<73::AID-PROS9>3.0.CO;2-V
- Morse MA. Denz Y. Coleman D. Hull S. Kitrell-Fisher Nair S: A phase I study of active immunotherapy with ca noembrvonic antigen peptide (CAP-I)-pulsed. autologous man cultured dendritic cells in patients with metastatic rna nancies expressing carcinoembryonic antigen. Clin Cancer Res 5:1331-1338. 1999
- Thurner B. Haendle I, Roger C. Dieckmann D. Keikavo P. Tonuleit H: Vaccination with Mage-3A1 peptide oul mature. monocyte-derived dendritic cells expands specific totoxic T cells and induces regression of some metastases advanced stage N melanoma. J Exp Med 190;1669-1678, 1999 https://doi.org/10.1084/jem.190.11.1669
- Brossart P. Wirths S. Stuhler G. Reichardt VL, Kanz L, Br ger W: Induction of cytotoxic T-lymphocyte responses vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96;3102-3108. 2000
- Holtl L, Reiser C. Papesh C. Ramoner R. Herold M. Klo H: Cellular and humoral immune responses in patients w metastatic renal cell carcinoma after vaccination with anti pulsed dendritic cells. J Urol 161;777-782. 1999 https://doi.org/10.1016/S0022-5347(01)61767-1
- Schott M. Feldkamp J. Schattenbera D. Krueger T. Dotzen th C. Seissler T: Induction of cellular immunity in a para roid carcinoma treated with tumor lysate pulsed dendr cells. Eur J Endocrinol 142;300-306. 2000 https://doi.org/10.1530/eje.0.1420300
- Geiger JD. Hutchinson RJ. Hohenkirk LF. McKenna E Yanik GA. Levine JE: Vaccination of pediatric solid tum patients with tumor lysate-pulsed dendritic cells can expa specific T cells and mediate tumor regression. Cancer Res 61:8513-8519. 2001
- Hernando Il. Park TW. Kubler K. Offerzeld R. Schlebu H. Bauknecht T: Vaccination with autologous tumor ant pulsed dendritic cells in advanced gynaecological malign cies: clinical and immunological evaluation of a phase I tr Cancer Immunol Immunother 51;45-52, 2002 https://doi.org/10.1007/s00262-001-0255-1
- Azuma T. Horie S, Tomita K. Takahashi T, Tanaka Y. Ka wase K: Dendritic cell imrnunotheranv for patients with tastatic renal cell carcinoma: University of Tokyo experie Int J Urology 9;340-346, 2002 https://doi.org/10.1046/j.1442-2042.2002.00477.x
- Amoscato AA, Prenovits DA. Lotz MT: Rapid extracell degradation of svnthetic class I oeotides by human dendr cells. J Immunol 161;4023-4032. 1998
- Souberbielle BE, Westbv M. Ganz S. Kavaza T. Mendes Morrow WTW, Dalgleish AG: Comparison of four strate for tumour vaccination in the B16-F10 melanoma mod Gene Ther 5;1447-1454. 1998 https://doi.org/10.1038/sj.gt.3300747
- Melcher A, Todryk S, Bateman A, Chong H. Lemoine Vile RG: Adoptive transfer of immature dendritic cells w autologous or allogeneic tumor cells generates systemic an tumor imrnunity. Cancer Res 59;2802-2805, 1999
- Berard F, Blanco P, Davoust J. Neidhart-Berard EM, Nou Shirazi M, Taouet N: Cross-priming of naive CD8 T c against melanoma antigens using dendritic cells loaded w killed allogeneic melanoma cells. J Exp Med 192;1535-1543, 2000 https://doi.org/10.1084/jem.192.11.1535
-
Jenne L Arrighi JF. Tonuleit H, Saurat JH, Hauser C: D dritic cells containing apoptotic melanoma cells prime hum
$CD8^+$ T cells for efficient tumor cell lysis. Cancer Res 60;4446-4452, 2000 - Holtl L Zelle-Rieser C. Gander H. Papesh C. Ramoner Bartsch G: Immunotherapv of metastatic renal cell carcino with autologous tumor Ivsate-nulsed dendritic cells. Scient Program and Abstract of 7th International Symposium Dendritic Cells, p145. 2002
- Bercovici N, Massicard S, Baron V, Pauillac F. Hamon Agrawal S: Immune responses in patients with metastatic m lanoma immunized with autologous DC loaded with an a zeneic melanoma cell lvsate. Scientific Program and Abstr of 7th International Symposium on Dendritic Cells, p1 2002
- Dematos P, Abdel-Wahab Z. Vervaert C, Hester D, Seiz H: Pulsing of dendritic cells with cell lvsates from either B melanoma or MCA-106 fibrosarcoma vields eouallv dffect vaccines against B16 tumors in mice. J Surg Oncol 68;79-91, 1998 https://doi.org/10.1002/(SICI)1096-9098(199806)68:2<79::AID-JSO3>3.0.CO;2-H
-
Yoon HL Singh K, Ratner S, Reiners TT: Phorbol ester fects on splenic lvmphocvte composition and cytotoxic T activities of SSIN mice: a strain deficient in
$CD8^+$ T cells. Carcinogenesis 17:2617-2624. 1996 https://doi.org/10.1093/carcin/17.12.2617 - Kemp R. Ronchese F: Tumor-specific Tcl, but not Tc2, c deliver protective antitumor immunity. J Immunol 167;6 6502. 2001
- Green EL: Handbook on Geneticallv Standardized JAX M New York. McGraw-Hill pp521-562, 1977
- Kripke ML: Speculations on the role of ultraviolet radiat in the development of malignant melanoma. J Natl Cancer Inst 63;541-548. 1979 https://doi.org/10.1093/jnci/63.3.541
- Cloudman AM: The effect of an extra-chromosomal influ ce upon transplanted spontaneous tumors in mice. Scien 93;380-381. 1941 https://doi.org/10.1126/science.93.2416.380
- Peter L Mezzacasa A. LeDonne P. Dummer R. Hemmi Comparative analvsis of immunocritical melanoma marker the mouse melanoma cell lines B16, K1735 and S91-M3. Melanoma Res 11;21-30, 2001 https://doi.org/10.1097/00008390-200102000-00003
- Palucka K. Banchereau T: Dendritic cells: a link between nate and adaptive imrnunity. J Clin Immunol 19:12-25, 1999 https://doi.org/10.1023/A:1020558317162
- Palucka K, Banchereau J: Linkinz innate and adaptive immnity, Nat Med 5;868-870. 1999 https://doi.org/10.1038/11303
- Fernandez N et al: Dendritic cells directlv trigger NK cell fu tions: Cross-talk relevant in innate anti-tumor immune sponses in vivo. Nature Medicine 5;405-410, 1999 https://doi.org/10.1038/7403